Literature DB >> 23793926

Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?

Burcu Esen Akkas1, Busra Bedriye Demirel, Aysen Dizman, Gulin Ucmak Vural.   

Abstract

UNLABELLED: The objective of this retrospective study was to evaluate the prognostic significance of volume-based metabolic markers of PET/CT along with clinical characteristics in patients with in-operable cervical carcinoma.
METHODS: Fifty-eight patients with cervical carcinoma (stage IIB-IVB) underwent FDG PET/CT for pretreatment evaluation and included in this study. Patients were staged according to International Federation of Gynecology and Obstetrics [FIGO] system. After chemoradiation therapy, patients were evaluated for persistent disease (PD) by clinical examinations, smear tests, pelvic MRI and PET/CT. Based upon follow-up results, clinical characteristics (patient age, tumor histology, FIGO stage) and PET/CT findings such as presence of PET-positive pelvic/para-aortic lymph nodes (LN), metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake values (SUVmax) of tumor and lymph nodes were analyzed for disease persistence. Survival analysis for disease-free survival and overall survival was performed with Kaplan-Meier method using PET findings and clinical characteristics.
RESULTS: At the time of last follow-up (mean: 22 ± 12.6 months, range 6-48), 38 patients (65 %) had PD, 20 patients (35 %) had no evidence of disease (NED). Patient age, tumor histology, MTV, TLG and tumor SUVmax did not differ between groups. The frequency of PET-positive pelvic/para-aortic lymph nodes (84 vs. 60 %, p = 0.03), LN SUVmax (10.2 vs. 6.5, p = 0.02), and FIGO stage differed significantly between PD and NED groups. Cox proportional hazards model demonstrated advanced FIGO stage and the presence of PET-positive para-aortic LN were independent predictors for PD. Both disease-free survival and overall survival curves showed progressive worsening as the disease advanced, p = 0.015. PET LN status was the most important prognostic indicator for disease-free survival and overall survival. The worst outcome curves were detected for patients with PET-positive para-aortic lymph nodes among all patients, p = 0.03.
CONCLUSION: Advanced FIGO stage and the presence of FDG-avid para-aortic lymph nodes on pretreatment PET/CT are significant prognostic biomarkers for PD and decreased overall survival in patients with in-operable cervical carcinoma independent from MTV, TLG, tumor and lymph node SUVmax.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23793926     DOI: 10.1007/s12149-013-0745-1

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  16 in total

1.  Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.

Authors:  Yoshiko Ueno; Robert Lisbona; Tsutomu Tamada; Amer Alaref; Kazuro Sugimura; Caroline Reinhold
Journal:  Br J Radiol       Date:  2017-06-16       Impact factor: 3.039

2.  Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.

Authors:  Ozan Cem Guler; Nese Torun; Berna Akkus Yildirim; Cem Onal
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

3.  Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.

Authors:  Si Gao; Siyao Du; Zaiming Lu; Jun Xin; Song Gao; Hongzan Sun
Journal:  Eur Radiol       Date:  2019-09-06       Impact factor: 5.315

4.  Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.

Authors:  Jennifer C Ho; Pamela K Allen; Priya R Bhosale; Gaiane M Rauch; Clifton D Fuller; Abdallah S R Mohamed; Michael Frumovitz; Anuja Jhingran; Ann H Klopp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-17       Impact factor: 7.038

5.  Value of integrated PET-IVIM MRI in predicting lymphovascular space invasion in cervical cancer without lymphatic metastasis.

Authors:  Chen Xu; Yang Yu; Xiaoran Li; Hongzan Sun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-27       Impact factor: 9.236

6.  Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer.

Authors:  Jennifer C Ho; Penny Fang; Carlos E Cardenas; Abdallah S R Mohamed; Clifton D Fuller; Pamela K Allen; Priya R Bhosale; Michael M Frumovitz; Anuja Jhingran; Ann H Klopp
Journal:  Radiother Oncol       Date:  2019-03-11       Impact factor: 6.280

7.  Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

Authors:  Marie Voglimacci; Erwan Gabiache; Amélie Lusque; Gwenaël Ferron; Anne Ducassou; Denis Querleu; Stéphanie Motton; Elodie Chantalat; Frédéric Courbon; Alejandra Martinez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-07       Impact factor: 9.236

8.  Quantitative differences in [(18)F] NaF PET/CT: TOF versus non-TOF measurements.

Authors:  Jorge D Oldan; Timothy G Turkington; Kingshuk Choudhury; Bennett B Chin
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

9.  Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational 18F-FDG PET/CT study.

Authors:  Siyao Du; Hongzan Sun; Si Gao; Jun Xin; Zaiming Lu
Journal:  Quant Imaging Med Surg       Date:  2019-03

10.  Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography.

Authors:  Mubarik A Arshad; Samuel Gitau; Henry Tam; Won-Ho E Park; Neva H Patel; Andrea Rockall; Eric O Aboagye; Nishat Bharwani; Tara D Barwick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-12-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.